September 08, 2017, the Food and Drug Administration (FDA) approved
Parker Hannifin’s request to expand Indego’s indications for use
is great news for patients!
This expansion is a significant change from the previous FDA
approved IFU, and now allows therapists to treat individuals with
spinal cord injury at levels C7 and lower in rehabilitation
institutions. Furthermore, it enables... Read More »